Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate cancer.

Telix announced that the Australian Therapeutic Goods Administration (TGA) has approved Illuccix® (Kit for the preparation of 68Ga PSMA-11 Injection) as a positron emission tomography (PET) agent for the diagnostic imaging of  prostate cancer, in

1. Patients with prostate cancer who are at risk of metastasis and who are suitable for initial definitive therapy (also known as “primary staging”), and

2. Patients with prostate cancer who have suspected recurrence based on elevated serum prostate specific antigen (PSA) level (also known as “biochemical recurrence”).

Illuccix®, after radiolabeling with gallium-68, is the first commercially approved PSMA-PET imaging agent available in Australia. The TGA approval of Illuccix facilitates wide-spread clinical access to prostate cancer imaging for all men across Australia including those in rural and regional areas, enabling the availability of state-of-the-art PSMA PET imaging across the country, says the announcement by Telix.

To read more please visit:

Australian TGA Approves Illuccix® for Prostate Cancer Imaging

Source: TELIX